TL;DR: Aetna, a CVS Health company, modified CPB 0985 covering margetuximab-cmkb (Margenza) billing, effective September 26, 2025. Here's what changes for billing teams.
Aetna updated CPB 0985 for margetuximab-cmkb (Margenza), the HER2-directed monoclonal antibody used in metastatic breast cancer. This modification affects claims billed under HCPCS J9353 and CPT codes 96413–96417 for intravenous chemotherapy administration. If your oncology or infusion center bills commercial Aetna plans for Margenza, your prior authorization workflow and documentation requirements need a hard review before the September 26, 2025 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Margetuximab-cmkb (Margenza) — CPB 0985 |
| Policy Code | CPB 0985 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Medical oncology, infusion therapy, hematology/oncology, hospital outpatient |
| Key Action | Verify precertification is in place for J9353 before submitting claims under commercial Aetna plans |
Aetna Margetuximab-cmkb Coverage Criteria and Medical Necessity Requirements 2025
The Aetna Margenza coverage policy applies to commercial medical plans only. Medicare criteria live separately — see Aetna's Medicare Part B step therapy page. Don't apply the commercial criteria to Medicare Advantage claims without verifying the plan-specific policy first.
Aetna covers margetuximab-cmkb (J9353) when it meets medical necessity criteria tied to a specific ICD-10 diagnosis: malignant neoplasm of the breast (C50.011–C50.929) with HER2-positive status, in the setting of metastatic, recurrent, or unresectable disease. That's a narrow diagnosis window. If the claim doesn't carry both the HER2-positive qualifier and the metastatic/recurrent/unresectable clinical context, expect a medical necessity denial.
The coverage policy requires precertification — full stop. There's no pathway to bill J9353 on a commercial Aetna plan without prior authorization in place. Call (866) 752-7021 or fax (888) 267-3277 to initiate. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.
Precertification applies to all Aetna participating providers and members in applicable plan designs. That means infusion centers, hospital outpatient departments, and physician offices all carry the same prior auth obligation. No exceptions carved out by site of service.
Aetna Margetuximab-cmkb Exclusions and Non-Covered Indications
The CPB 0985 policy language scopes coverage tightly to HER2-positive metastatic breast cancer (C50.011–C50.929) with recurrent or unresectable disease. Anything outside that — early-stage HER2-positive breast cancer, HER2-negative disease, or off-label use in other solid tumors — isn't covered under this policy.
Aetna hasn't published a separate experimental/investigational designation for margetuximab-cmkb in this CPB, but the absence of a covered indication is a coverage denial in practice. If a clinical team asks about using Margenza outside metastatic or unresectable breast cancer, the answer under CPB 0985 is no coverage on commercial plans.
The real exposure here is billing J9353 on a claim where the ICD-10 code doesn't support the HER2-positive metastatic context. A diagnosis code that looks like breast cancer but doesn't reflect advanced or recurrent disease is enough to trigger a claim denial. Get the diagnosis coding right before submission.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| HER2-positive metastatic breast cancer (unresectable or recurrent) | Covered | J9353, C50.011–C50.929 | Precertification required; commercial plans only |
| Chemotherapy administration, IV infusion (initial/subsequent hours) | Covered (when J9353 covered) | 96413, 96414, 96415, 96416, 96417 | Billed in conjunction with J9353; subject to plan design |
| Breast cancer — HER2-negative, early-stage, or non-metastatic | Not Covered | — | Outside CPB 0985 indication; expect denial |
| Off-label use in other solid tumors | Not Covered | — | No covered indication under CPB 0985 |
| Medicare patients (any indication) | See Medicare Part B criteria | — | CPB 0985 is commercial only; Medicare criteria separate |
Aetna Margetuximab-cmkb Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Verify precertification before September 26, 2025 for any pending Margenza cases. The effective date for this modification is September 26, 2025. Any commercial Aetna claim for J9353 without an authorization on file is a claim denial waiting to happen. If you have patients mid-treatment, confirm existing auths cover the full treatment course under the updated CPB 0985 criteria. |
| 2 | Use HCPCS J9353 as your drug code — not a miscellaneous J-code. J9353 is the specific HCPCS code for margetuximab-cmkb, billed per 5 mg. Bill the exact units based on the dose administered. Billing a miscellaneous chemotherapy code (anything from J9000–J9999 not specifically assigned) when a specific J-code exists is a common reimbursement error and a frequent audit flag. |
| 3 | Link the correct ICD-10 range on every claim. The covered diagnosis is C50.011–C50.929 for malignant neoplasm of the breast, but the clinical context must reflect HER2-positive status with metastatic, recurrent, or unresectable disease. Confirm your coding team understands this is not a blanket breast cancer code — the documentation must support advanced disease. If the medical record doesn't document HER2-positivity and metastatic/unresectable status explicitly, the claim is vulnerable on medical necessity review. |
| 4 | Bill chemotherapy administration codes 96413–96417 correctly alongside J9353. CPT 96413 covers the initial hour of IV infusion for chemotherapy. CPT 96415 covers each additional hour. CPT 96414 covers concurrent infusion, 96416 covers initiation of highly complex agent(s), and 96417 covers each additional sequential infusion. Choose the right combination based on what actually happened in the infusion suite — don't default to 96413 alone if additional hours were administered. Incorrect administration code selection reduces reimbursement and creates audit exposure. |
| 5 | Collect precertification documentation before the infusion, not after. Retrospective auth requests for Margenza are rarely successful. Call (866) 752-7021 or fax the SMN form to (888) 267-3277 before the first infusion in a treatment course. For your commercial Aetna patients, build a prior authorization checkpoint into your treatment order workflow. |
| 6 | Separate your Medicare and commercial Aetna workflows for this drug. CPB 0985 is commercial only. Medicare criteria for margetuximab-cmkb live on Aetna's Medicare Part B step therapy page — the criteria differ. If your billing team applies the same documentation to both payer types, you're likely under-documenting for one of them. Build separate checklists. |
| 7 | If your payer mix includes Aetna Medicare Advantage plans, confirm which criteria apply. Medicare Advantage plan designs vary. Some Aetna MA plans follow CMS criteria, others align to commercial CPB criteria for specific drugs. If you're not sure which criteria govern a specific MA plan, call Aetna provider relations or talk to your compliance officer before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Margetuximab-cmkb Under CPB 0985
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9353 | HCPCS | Injection, margetuximab-cmkb, 5 mg |
Other HCPCS Codes Related to CPB 0985
| Code | Type | Description |
|---|---|---|
| J9000–J9999 | HCPCS Range | Chemotherapy drugs (general range) |
CPT Codes — Chemotherapy Administration (IV Infusion)
These codes apply to the infusion administration of margetuximab-cmkb. They're not stand-alone covered codes — they're billed in conjunction with J9353 when the drug itself meets coverage criteria.
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug |
| 96414 | CPT | Chemotherapy administration, intravenous infusion technique; concurrent infusion |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique; each additional hour |
| 96416 | CPT | Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than eight hours), requiring use of a portable or implantable pump |
| 96417 | CPT | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to one hour |
Key ICD-10-CM Diagnosis Codes
| Code Range | Description |
|---|---|
| C50.011–C50.929 | Malignant neoplasm of breast — HER2-positive, metastatic, recurrent, or unresectable disease |
The full C50 range covers laterality and subsite specificity. Your coder needs to select the specific code reflecting the patient's anatomy (right vs. left breast, subsite) — don't default to an unspecified code if the record supports greater specificity. Unspecified codes on high-cost oncology claims draw scrutiny.
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.